Top

Published in:

Open Access 01-12-2018 | Research article

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma

Authors: Urs Giger-Pabst, Cédric Demtröder, Thomas A. Falkenstein, Mehdi Ouaissi, Thorsten O. Götze, Günther A. Rezniczek, Clemens B. Tempfer

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options.

Methods

We performed a retrospective cohort study of patients with recurrent MM undergoing Pressurized IntraPeritoneal/Thoracal Aerosol Chemotherapy (PIPAC/PITAC) with doxorubicin 1.5 mg/m² and cisplatin 7.5 mg/m². Data were retrospectively collected in a prospective registry of patients undergoing PIPAC/PITAC. Study outcomes were microscopic tumor regression grade (TRG), survival and adverse events (v4.0 CTCAE).

Results

A total of 29 patients (m/f = 17/12) with MM with a mean age of 62.4 (range: 42 to 84) years were analyzed. A total of 74 PIPAC and 5 PITAC procedures were performed. The mean number of PIPAC applications was 2.5 (range: 0 to 10) per patient. Twenty patients (69%) had > 2 PIPAC procedure and were eligible for TRG analysis. TRG 1 to 4 was observed in 75% (15/20) of patients. Major regression (TRG 3) or complete regression (TRG 4) was observed in 20% and 10%, respectively. PIPAC induced significant tumor regression in 51.7% (15/29) of patients with a cumulative effect after repetitive PIPACs (PIPAC #1 vs. PIPAC #2: p = 0.001; PIPAC #1 vs. PIPAC #3: p = 0.001; PIPAC #1 vs. PIPAC #4: p = 0.001). Postoperative CTCAE grade 4 complications were observed in two patients (6.9%) who had cytoreductive surgery (CC2) and intraoperative PIPAC. One patient (3.4%) died due to postoperative kidney insufficiency. After a follow up of 14.4 (95% CI: 8.1 to 20.7) months after the last PIPAC/PITAC application, median overall survival was 26.6 (95% CI: 9.5 to 43.7) months (from the first application).

Conclusion

After prior abdominal surgery and systemic chemotherapy, repetitive PIPAC applications are feasible and safe for patients with end-stage MM. Furthermore, PIPAC induces significant histological regression of malignant mesothelioma in the majority of patients. PITAC is feasible, but its safety and efficacy to control malignant pleural effusion remain unclear.

Available only for authorised users

American Cancer Society. (2013, December 19). Malignant mesothelioma. http://www.cancer.org/acs/groups/cid/documents/webcontent/003119-pdf.pdf.

Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–91.CrossRefPubMed

Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–603.CrossRefPubMed

Bani-Hani KE, Gharaibeh KA. Malignant peritoneal mesothelioma. J Surg Oncol. 2005;91:17–25.CrossRefPubMed

Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A. Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori. 2005;91(3):276–9.PubMed

Al-Qahtani M, Morris B, Dawood S, Onerheim R. Malignant mesothelioma of the tunica vaginalis. Can J Urol. 2007;14(2):3514–7.PubMed

Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the north western Cape Province. Br J Ind Med. 1960;17:260–71.PubMedPubMedCentral

Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal Mesothelioma: A Review. MedGenMed. 2007;9(2):32.PubMedPubMedCentral

Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a r eview. Ann Transl Med. 2017;5(11):236. https://doi.org/10.21037/atm.2017.03.96.CrossRefPubMedPubMedCentral

10.

Neumann V, Löseke S, Nowak D, Herth FJ, Tannapfel A. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int. 2013;110(18):319–26. https://doi.org/10.3238/arztebl.2013.0319. PubMedPubMedCentral

11.

Fujimoto E, Kijima T, Kuribayashi K, Negi Y, Kanemura S, Mikami K, Doi H, Kitajima K, Nakano T. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17(9):865–72. https://doi.org/10.1080/14737140.2017.1340157. CrossRefPubMed

12.

Shavelle R, Vavra-Musser K, Lee J, Brooks J. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:2782590. https://doi.org/10.1155/2017/2782590.CrossRefPubMedPubMedCentral

13.

Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93. https://doi.org/10.1245/s10434-014-3978-x.CrossRefPubMed

14.

Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98(4):268–72. https://doi.org/10.1002/jso.21055.CrossRefPubMed

15.

Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Tanimura H, Tsubota YT. Chemotherapy and Serum hyaluronic acid levels in malignant peritoneal mesothelioma. Hepato-Gastroenterology. 2004;51(58):1073–83.PubMed

16.

Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9. https://doi.org/10.1245/s10434-013-3213-1.CrossRefPubMed

17.

Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017;104(6):669–78. https://doi.org/10.1002/bjs.10521.CrossRefPubMed

18.

Jonscher N, Hummels M, Giger-Pabst U, Karjalainen E, Zieren J, Büchner N, Reymond MA, Beshay M. Pressurized IntraThoracic aerosol chemotherapy (PITAC). In: Solass W, Reymond MA, editors. PIPAC: pressurized intraperitoneal aerosol chemotherapy – Cancer under pressure. Berlin/Boston: Walter de Gruyter Gmbh; 2014. p. 183–6.

19.

Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016;18(4):364–71. https://doi.org/10.1111/codi.13130.CrossRef

20.

Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.CrossRef

21.

Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute.

22.

Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827–34.CrossRefPubMed

23.

Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244(1):106–12.CrossRefPubMedPubMedCentral

24.

Philibert J. One and a half century of diffusion: Fick, Einstein, before and beyond. Diffusion Fundamentals. 2006;4:6.1–6.19.

25.

Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized intra peritoneal aerosol chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS One. 2017;12(10):e0186709. https://doi.org/10.1371/journal.pone.0186709. eCollection 2017.CrossRefPubMedPubMedCentral

26.

Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal Carcinomatosis: a cohort study. Anticancer Res. 2015;35(12):6723–9.PubMed

27.

Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, Quenet F, Glehen O, Bakrin N, Passot G. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(11):2178–83. https://doi.org/10.1016/j.ejso.2017.09.010.CrossRefPubMed

28.

Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U. Exploring the spatial drug distribution pattern of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2016;23(4):1220–4. https://doi.org/10.1245/s10434-015-4954-9.CrossRefPubMed

29.

Khosrawipour V, Khosrawipour T, Kern AJ, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Clin Oncol. 2016;142(11):2275–80. https://doi.org/10.1007/s00432-016-2234-0.CrossRef

30.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40–6.CrossRefPubMed

Title: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
Authors: Urs Giger-Pabst
Cédric Demtröder
Thomas A. Falkenstein
Mehdi Ouaissi
Thorsten O. Götze
Günther A. Rezniczek
Clemens B. Tempfer
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4363-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy - A Nationwide Danish Cohort Study

Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer

Dairy products and colorectal cancer in middle eastern and north African countries: a systematic review

Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system

Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma

Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer